Robert L. Coleman, MD, on Ovarian Cancer: Results From an NRG Oncology/Gynecologic Oncology Group Trial
2018 ASCO Annual Meeting
Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab, in platinum-sensitive, recurrent ovarian cancer (Abstract 5501).
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).
Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, discusses genome-wide sequencing for early-stage lung cancer detection from plasma cell–free DNA (Abstract LBA8501).
Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.
Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings on taselisib plus fulvestrant vs fulvestrant in patients with estrogen receptor–positive, PIK3CA-mutant, locally advanced or metastatic breast cancer (Abstract LBA1006).